Allogeneic and Autologous Anti-CD7 CAR-T Cell Therapies in Relapsed or Refractory T Cell Malignancies

被引：2
|
作者：
Zhang, Yinqiang [1 ,2 ]
Li, Chenggong [1 ,2 ]
Jiang, Huiwen [1 ,2 ]
Luo, Wenjing [1 ,2 ]
Du, Mengyi [1 ,2 ]
Zhou, Fen [1 ,3 ]
Tang, Lu [1 ,2 ]
Wu, Jianghua [1 ,2 ]
Wei, Qiuzhe [1 ,2 ]
Lu, Cong [1 ,2 ]
Kou, Haiming [1 ,2 ]
Wu, Di [4 ]
Alex, Chang H. [5 ]
Mei, Heng [1 ,2 ]
Hu, Yu [1 ,2 ]
机构：
[1] Hubei Clin Med Ctr Cell Therapy Neoplast Dis, Wuhan, Peoples R China
[2] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Inst Hematol, Wuhan, Peoples R China
[3] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pediat, Wuhan, Peoples R China
[4] Beijing GoBrd Hosp Management Co Ltd, Beijing, Peoples R China
[5] Shanghai YaKe Biotechnol Ltd, Shanghai, Peoples R China
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-170819
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4592 / 4594
页数：3
相关论文
共 50 条
  • [41] CD19 CAR-T Cell Therapy in Children with Relapsed and Refractory B-ALL
    Molostova, Olga
    Shelikhova, Larisa
    Muzalevsky, Yakov
    Kazachenok, Alexey
    Khismatullina, Rimma
    Abugova, Julia
    Kurnikova, Elena
    Trakhtman, Pavel
    Pershin, Dmitry
    Zubachenko, Viktoria
    Fadeeva, Maria
    Popov, Alexander M.
    Illarionova, Olga
    Miakova, Natalia
    Litvinov, Dmitry
    Novichkova, Galina
    Maschan, Alexey
    Maschan, Michael
    BLOOD, 2021, 138
  • [42] HIGH SAFETY AND EFFICACY OF ANTI-CD7 CAR-T CELLS IN TREATING RELAPSED OR REFRACTORY CD7+ACUTE MYELOID LEUKEMIA: FIRST-IN-HUMAN PHASE I STUDY
    Hu, Yongxian
    Zhang, Mingming
    Zhao, Houli
    Wei, Guoqing
    Chang, Alex Hongsheng
    Huang, He
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 44 - 45
  • [43] CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia
    Liu, Jun
    Zhang, Xi
    Zhong, Jiang F.
    Zhang, Cheng
    IMMUNOTHERAPY, 2017, 9 (13) : 1115 - 1125
  • [44] CAR-T cell therapy in relapsed or refractory multiple myeloma and access in Turkey
    Hakan, Goker
    Engin, Kelkitli
    Elifcan, Karakulak Aladag
    Haluk, Demiroglu
    Mehmet, Turgut
    Suman, Kambhampati
    Maxwell, Krem
    FRONTIERS IN MEDICINE, 2024, 11
  • [45] Relapsed/refractory large B-cell lymphoma CAR-T cell therapies continue to gain importance in everyday treatment
    Walter, Monika
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (09) : 446 - 448
  • [46] Relapsed/refractory large B-cell lymphoma CAR-T cell therapies continue to gain importance in everyday treatment
    不详
    ACTA HAEMATOLOGICA, 2024, 147 (05) : 612 - 614
  • [47] T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies
    Tang, Lu
    Zhang, Yinqiang
    Hu, Yu
    Mei, Heng
    BIOMED RESEARCH INTERNATIONAL, 2021, 2021
  • [48] CD19/CD22 CAR-T Cell Cocktail Therapy Following Autologous Transplantation in Patients with Relapsed/Refractory B-Cell Lymphomas
    Cao, Yang
    Xiao, Yi
    Wang, Na
    Wang, Gaoxiang
    Zhou, Xiaoxi
    Huang, Liang
    Chen, Liting
    Xiao, Min
    Zhang, Tongcun
    Zhang, Yicheng
    Zhou, Jianfeng
    BLOOD, 2020, 136
  • [49] Targeting T cell malignancies with gene edited CAR-T
    Dipersio, John F.
    Cooper, Matthew
    CANCER RESEARCH, 2018, 78 (13)
  • [50] Novel CAR-T Cell Therapies in China
    Chang, Lung-Ji
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S3 - S4
12345